Historical Staging: The Durie-Salmon system classifies myeloma based on estimated tumor cell mass. Note: Modern clinical practice primarily uses the Revised-ISS (R-ISS).
Laboratory Parameters
Bone & Protein
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Historical classification and staging of Multiple Myeloma.
Estimating myleoma cell mass based on clinical and laboratory parameters.
Educational or retrospective data analysis (note: largely superseded by R-ISS).
Patient Population
Patients with confirmed Multiple Myeloma. Historically used to differentiate low, intermediate, and high tumor burden.
When Not to Rely on This Score Alone
Modern prognostication — the Revised International Staging System (R-ISS) is the current gold standard, incorporating LDH and cytogenetics.
Monitoring response — use IMWG response criteria (e.g., sCR, VGPR, PR) rather than staging systems.
Section 2
Formula & Logic
Stage I (Low Cell Mass)
Haemoglobin > 10 g/dL
Serum Calcium < 12 mg/dL
Normal bone x-ray or solitary plasmacytoma
Low M-protein: IgG < 5 g/dL, IgA < 3 g/dL, Bence Jones < 4g/24h
Stage III (High Cell Mass)
Haemoglobin < 8.5 g/dL
Serum Calcium > 12 mg/dL
Advanced lytic bone lesions (≥ 3)
High M-protein: IgG > 7 g/dL, IgA > 5 g/dL, Bence Jones > 12g/24h
Stage II (Intermediate)
Neither Stage I nor Stage III.
Substaging (Renal Function)
Substage
Criteria
A
Serum Creatinine < 2.0 mg/dL
B
Serum Creatinine ≥ 2.0 mg/dL
Section 3
Pearls/Pitfalls
Historical Context
The Durie-Salmon system (1975) was revolutionary because it correlated clinical symptoms with actual myeloma cell burden. However, it was limited by the need for diagnostic x-rays and subjective bone lesion counts, which are less sensitive than modern low-dose CT or MRI.
Section 4
Evidence Appraisal
Primary Score
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
Developed by Brian Durie and Sydney Salmon at the University of Arizona. It dominated myeloma staging for three decades until the ISS (2005) gained prominence.